News & Events

Lucence Showcases Promising Data on ctDNA and ctRNA Liquid Biopsy Assay for Lung Cancer at 2022 ASCO Annual Meeting

Lucence Announces Publication of Validation Study for LiquidHALLMARK ctDNA Liquid Biopsy Assay

Lucence’s LiquidHALLMARK Liquid Biopsy Assay Expands to Include cfRNA

Lucence Launches First Liquid Biopsy Screening Study in Partnership with the VA Palo Alto Healthcare System

AstraZeneca and Lucence Collaborate in South-East Asia to bring HRD Testing to Ovarian Cancer Patients to guide PARPi Treatment

Lucence and Yemaachi Launch the AMBER Study to Detect and Characterize Genomic Alterations in Breast Cancer in Women in Africa and Expand Liquid Biopsy Access

Lucence Presents Data at ESMO 2021 Showing Liquid Biopsy Detects Actionable Genomic Alterations in Bladder Cancer Patients Undergoing Immunotherapy

Lucence Announces Commercial Availability of Tissue500™ for Comprehensive Targeted Therapy Matching